Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice

Yoshiaki Kanaya, Hiroyoshi Doihara, Kouji Shiroma, Yutaka Ogasawara, Hiroshi Date

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose. We evaluated the effects of combined treatment with the antiestrogen agent toremifene (TOR) and local hyperthermia (LHT) on the MCF-7 breast cancer cell line. Methods. BALB/c mice implanted with MCF-7 cells were divided into six treatment groups: a control group, a TOR30 group (given 30 mg/kg/day), a TOR120 group (given 120 mg/kg/day), an LHT group (43.5°C), a TOR30 + LHT group, and a TOR120 + LHT group. The effects of the treatments on tumor cells, estrogen receptor (ER) expression, and cell cycle kinetics were measured after 21 days. We calculated the apoptotic index and vascular density inside the tumors and evaluated the efficacy of the transmigration of TOR into the tumors. Results. The antitumor effects were significantly greater in both combined therapy groups than in any of the single therapy groups. Estrogen receptor expression was weaker in the combined therapy groups than in the single therapy groups, and there were more G0/G1-phase cells and fewer S-phase cells in both combined therapy groups than in the single therapy groups. The apoptotic index was increased and the tumor vascular density was decreased in the combined therapy groups. Conclusions. We attributed the effects of this combined therapy to the induction of apoptosis, the decrease in vascular density, and the increase and decrease in G0/G1-phase and S-phase cells, respectively, in the tumors.

Original languageEnglish
Pages (from-to)911-920
Number of pages10
JournalSurgery Today
Volume38
Issue number10
DOIs
Publication statusPublished - Oct 2008

Fingerprint

Toremifene
Induced Hyperthermia
Estrogen Receptor Modulators
Group Psychotherapy
Nude Mice
Breast Neoplasms
Blood Vessels
Cell Cycle Resting Phase
G1 Phase
Neoplasms
S Phase
Estrogen Receptors
Therapeutics
MCF-7 Cells
Cell Cycle
Apoptosis
Cell Line
Control Groups

Keywords

  • Angiogenesis
  • Apoptosis
  • Breast cancer
  • Hyperthermia
  • Toremifene

ASJC Scopus subject areas

  • Surgery

Cite this

Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice. / Kanaya, Yoshiaki; Doihara, Hiroyoshi; Shiroma, Kouji; Ogasawara, Yutaka; Date, Hiroshi.

In: Surgery Today, Vol. 38, No. 10, 10.2008, p. 911-920.

Research output: Contribution to journalArticle

Kanaya, Yoshiaki ; Doihara, Hiroyoshi ; Shiroma, Kouji ; Ogasawara, Yutaka ; Date, Hiroshi. / Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice. In: Surgery Today. 2008 ; Vol. 38, No. 10. pp. 911-920.
@article{37875bcf668c4808909945070e377808,
title = "Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice",
abstract = "Purpose. We evaluated the effects of combined treatment with the antiestrogen agent toremifene (TOR) and local hyperthermia (LHT) on the MCF-7 breast cancer cell line. Methods. BALB/c mice implanted with MCF-7 cells were divided into six treatment groups: a control group, a TOR30 group (given 30 mg/kg/day), a TOR120 group (given 120 mg/kg/day), an LHT group (43.5°C), a TOR30 + LHT group, and a TOR120 + LHT group. The effects of the treatments on tumor cells, estrogen receptor (ER) expression, and cell cycle kinetics were measured after 21 days. We calculated the apoptotic index and vascular density inside the tumors and evaluated the efficacy of the transmigration of TOR into the tumors. Results. The antitumor effects were significantly greater in both combined therapy groups than in any of the single therapy groups. Estrogen receptor expression was weaker in the combined therapy groups than in the single therapy groups, and there were more G0/G1-phase cells and fewer S-phase cells in both combined therapy groups than in the single therapy groups. The apoptotic index was increased and the tumor vascular density was decreased in the combined therapy groups. Conclusions. We attributed the effects of this combined therapy to the induction of apoptosis, the decrease in vascular density, and the increase and decrease in G0/G1-phase and S-phase cells, respectively, in the tumors.",
keywords = "Angiogenesis, Apoptosis, Breast cancer, Hyperthermia, Toremifene",
author = "Yoshiaki Kanaya and Hiroyoshi Doihara and Kouji Shiroma and Yutaka Ogasawara and Hiroshi Date",
year = "2008",
month = "10",
doi = "10.1007/s00595-007-3730-2",
language = "English",
volume = "38",
pages = "911--920",
journal = "Japanese Journal of Surgery",
issn = "0941-1291",
publisher = "Springer Japan",
number = "10",

}

TY - JOUR

T1 - Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice

AU - Kanaya, Yoshiaki

AU - Doihara, Hiroyoshi

AU - Shiroma, Kouji

AU - Ogasawara, Yutaka

AU - Date, Hiroshi

PY - 2008/10

Y1 - 2008/10

N2 - Purpose. We evaluated the effects of combined treatment with the antiestrogen agent toremifene (TOR) and local hyperthermia (LHT) on the MCF-7 breast cancer cell line. Methods. BALB/c mice implanted with MCF-7 cells were divided into six treatment groups: a control group, a TOR30 group (given 30 mg/kg/day), a TOR120 group (given 120 mg/kg/day), an LHT group (43.5°C), a TOR30 + LHT group, and a TOR120 + LHT group. The effects of the treatments on tumor cells, estrogen receptor (ER) expression, and cell cycle kinetics were measured after 21 days. We calculated the apoptotic index and vascular density inside the tumors and evaluated the efficacy of the transmigration of TOR into the tumors. Results. The antitumor effects were significantly greater in both combined therapy groups than in any of the single therapy groups. Estrogen receptor expression was weaker in the combined therapy groups than in the single therapy groups, and there were more G0/G1-phase cells and fewer S-phase cells in both combined therapy groups than in the single therapy groups. The apoptotic index was increased and the tumor vascular density was decreased in the combined therapy groups. Conclusions. We attributed the effects of this combined therapy to the induction of apoptosis, the decrease in vascular density, and the increase and decrease in G0/G1-phase and S-phase cells, respectively, in the tumors.

AB - Purpose. We evaluated the effects of combined treatment with the antiestrogen agent toremifene (TOR) and local hyperthermia (LHT) on the MCF-7 breast cancer cell line. Methods. BALB/c mice implanted with MCF-7 cells were divided into six treatment groups: a control group, a TOR30 group (given 30 mg/kg/day), a TOR120 group (given 120 mg/kg/day), an LHT group (43.5°C), a TOR30 + LHT group, and a TOR120 + LHT group. The effects of the treatments on tumor cells, estrogen receptor (ER) expression, and cell cycle kinetics were measured after 21 days. We calculated the apoptotic index and vascular density inside the tumors and evaluated the efficacy of the transmigration of TOR into the tumors. Results. The antitumor effects were significantly greater in both combined therapy groups than in any of the single therapy groups. Estrogen receptor expression was weaker in the combined therapy groups than in the single therapy groups, and there were more G0/G1-phase cells and fewer S-phase cells in both combined therapy groups than in the single therapy groups. The apoptotic index was increased and the tumor vascular density was decreased in the combined therapy groups. Conclusions. We attributed the effects of this combined therapy to the induction of apoptosis, the decrease in vascular density, and the increase and decrease in G0/G1-phase and S-phase cells, respectively, in the tumors.

KW - Angiogenesis

KW - Apoptosis

KW - Breast cancer

KW - Hyperthermia

KW - Toremifene

UR - http://www.scopus.com/inward/record.url?scp=52949144931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949144931&partnerID=8YFLogxK

U2 - 10.1007/s00595-007-3730-2

DO - 10.1007/s00595-007-3730-2

M3 - Article

C2 - 18820866

AN - SCOPUS:52949144931

VL - 38

SP - 911

EP - 920

JO - Japanese Journal of Surgery

JF - Japanese Journal of Surgery

SN - 0941-1291

IS - 10

ER -